VVOS

VVOS

USD

Vivos Therapeutics Inc. Common Stock

$2.684-0.006 (-0.204%)

Real-time Price

Healthcare
Medical devices
United States

Price Chart

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$2.690

High

$2.690

Low

$2.600

Volume

0.00M

Company Fundamentals

Market Cap

16.3M

Industry

Medical devices

Country

United States

Trading Stats

Avg Volume

0.12M

Exchange

NCM

Currency

USD

52-Week Range

Low $1.91Current $2.684High $6.28

Related News

GlobeNewswire

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this

View more
Vivos Therapeutics Signs Definitive Agreement to  Acquire Largest Sleep Center Operator in Nevada
Analyst Upgrades

Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $6.2

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics with a Buy and lowers the price target from $6.6 to $6.2.

View more
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $6.2
GlobeNewswire

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31,

View more
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update
GlobeNewswire

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and

View more
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call